Search results for "Vaccinations"
More clarity on myocarditis with mRNA COVID-19 vaccines
The classic presentation for COVID-19 vaccine-associated myocarditis is chest pain one to seven days after vaccination, with a median time of three days after vaccination, particularly after the second dose.
https://immattersacp.org/archives/2023/02/more-clarity-on-myocarditis-with-mrna-covid-19-vaccines.htm
1 Feb 2023
CDC recommendations on COVID-19 vaccine boosters, new data on vaccine effectiveness
Several groups in the U.S. are now eligible to receive a booster dose of the Pfizer-BioNTech COVID-19 vaccine at least six months after completing the initial two-dose series.
https://immattersacp.org/weekly/archives/2021/09/28/1.htm
28 Sep 2021
COVID-19 research focused on anticoagulation, vaccine-induced thrombocytopenia
Two new studies support prophylactic, rather than therapeutic, anticoagulation for COVID-19 patients, and case reports provide more information about vaccine-induced immune thrombotic thrombocytopenia.
https://immattersacp.org/weekly/archives/2021/06/15/1.htm
15 Jun 2021
Transforming health care to improve U.S. life expectancy
The sobering decline in U.S. life expectancy reaffirms the exigency of health care reform anchored in a proactive and comprehensive approach.
https://immattersacp.org/archives/2023/10/transforming-health-care-to-improve-us-life-expectancy.htm
1 Oct 2023
Monkeypox: 5 key points
An expert panel convened by ACP and Annals of Internal Medicine provided five key takeaways about diagnosing and managing monkeypox.
https://immattersacp.org/archives/2022/11/monkeypox-5-key-points.htm
1 Nov 2022
New research adds to data on symptoms after COVID-19, vaccines' effects
Several COVID-19 studies looked at persistent symptoms, while new vaccine research found limited antibody responses in some patients and advised on tests for clotting complications. Other studies quantified the target population for tocilizumab treatment and gender differences in infections.
https://immattersacp.org/weekly/archives/2021/05/25/1.htm
25 May 2021
Many recent studies reporting on COVID-19 vaccines' safety, effectiveness
New studies looked at the safety of the adenovirus COVID-19 vaccines, the effectiveness of almost all the vaccines, and the impacts of COVID-19 infection in pregnancy and on long-term cardiac function. A physician columnist addressed pandemic-related anger.
https://immattersacp.org/weekly/archives/2021/05/11/1.htm
11 May 2021
Treatment for high-risk COVID-19 patients, vaccine news, research on health messaging
An industry-funded study found benefit with bamlanivimab plus etesevimab for high-risk ambulatory COVID-19 patients, the FDA noted a possible increased risk for Guillain-Barré syndrome with the Johnson & Johnson (Janssen) vaccine, and two studies looked at COVID-19 messaging for minority populations.
https://immattersacp.org/weekly/archives/2021/07/20/1.htm
20 Jul 2021
New research on Pfizer pill, mental disorders after COVID-19, vaccine reactions
A manufacturer-funded trial quantified the effectiveness of nirmatrelvir/ritonavir in outpatients. A retrospective study found veterans had more mental health diagnoses and received more antidepressants, benzodiazepines, and opioids after COVID-19, while two other studies looked at reactions to second and third doses of the vaccines.
https://immattersacp.org/weekly/archives/2022/02/22/1.htm
22 Feb 2022
New research on PASC, COVID-19 infection and vaccination during pregnancy
Two studies analyzed postacute sequelae of COVID-19 (PASC) in older and ICU patients. Other new research showed that symptomatic infection during delivery raised risks in pregnant women but vaccination during pregnancy was safe. An ACP/Annals of Internal Medicine forum focused on outpatient management of COVID-19, and the FDA issued an emergency use authorization for a new monoclonal antibody treatment.
https://immattersacp.org/weekly/archives/2022/02/15/1.htm
15 Feb 2022